Acute myeloid leukemia.
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has improved significantly during the past 3 decades. Further improvements in outcomes of children who have AML probably will reflect continued progress in understanding the biology of AML and the concomitant development of new molecularly targeted agents for use in combination with conventional chemotherapy drugs.
Rubnitz
Jeffrey E
JE
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. jeffrey.rubnitz@stjude.org
Gibson
Brenda
B
Smith
Franklin O
FO
D000293:Adolescent; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D010597:Pharmacogenetics; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors; D033581:Stem Cell Transplantation
D018943:Anthracyclines; D003561:Cytarabine